Adicet Bio, Inc. (ACET) · Nov 5, 2026 · Earnings

Adicet Bio earnings miss as lupus catalysts remain unchanged

Miss — EPS loss $1.76 vs ~$1.58 consensus

Adicet Bio’s Q3 earnings missed the published EPS estimate, while the lupus program advanced mainly through previously disclosed milestones.

Adicet is a clinical-stage biotech building its story around prula-cel as a potential one-time treatment for lupus, while advancing ADI-212 in prostate cancer and an earlier in vivo CAR-T platform. The key lupus efficacy update—50% complete renal response and 54% DORIS remission at 12 months—was already disclosed on September 28, 2026, so this filing is mainly a quarterly financial check-in and milestone confirmation.

The quarter missed the published EPS bar. Adicet reported a $1.76 per-share loss versus a published Q3 consensus of approximately $1.58, making the clean earnings read a miss rather than an in-line result.

Q3 2026Q3 2025Consensus
Net loss per share (Income Statement)$1.76$4.72$1.58 loss
Net loss (Income Statement)$18.9M$26.9M
R&D expense (Income Statement)$15.6M$22.9M
Cash and short-term investments (Balance Sheet)$100.9M$158.5M at Dec. 31, 2025

The business milestones are advancing, but this filing adds little surprise. The company says pivotal lupus-nephritis study startup is underway and plans FDA discussions about expanding into non-renal lupus; both were already telegraphed in the September clinical update. 〔0〕 The same is true of ADI-212, where the IND clearance, Fast Track designation, and planned first-quarter 2027 enrollment were already known. 〔1〕

Cash still supports the next development steps, not commercial independence. The $100.9 million cash balance is down from $158.5 million at year-end, but management says it should fund operating expenses into the second half of 2027. 〔2〕 That gives the company room to reach the next lupus and ADI-212 milestones without an immediately disclosed financing need, though the runway remains tied to execution and spending.

Bottom line: This was a modest earnings miss, while the clinical story remains intact but largely unchanged from the late-September disclosure. The filing slightly weakens the near-term read because the financial result fell short, but it does not materially alter Adicet’s development path. ⟧src: Prula-cel demonstrated positive safety and efficacy data in Phase 1 trial of patients with SLE with or without LN.⟧

What to watch next

Q4 FDA engagement; Q1 2027 12-month lupus data

Original filing on SEC EDGAR

Adicet Bio earnings miss as lupus catalysts remain unchanged | ACET Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.